US 12,411,147 B2
Erythrocyte-derived extracellular vesicles and proteins associated with such vesicles as biomarkers for Parkinson's disease
Francesca Cicchetti, Québec (CA); and Eric Boilard, Québec (CA)
Assigned to Université Laval, Québec (CA)
Filed by Université Laval, Québec (CA)
Filed on Sep. 5, 2023, as Appl. No. 18/306,992.
Application 18/306,992 is a continuation of application No. 16/484,073, granted, now 11,662,352, previously published as PCT/CA2018/050150, filed on Feb. 9, 2018.
Claims priority of provisional application 62/457,350, filed on Feb. 10, 2017.
Prior Publication US 2023/0408532 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); C12Q 1/32 (2006.01); C12Q 1/34 (2006.01); G01N 1/28 (2006.01); G01N 33/50 (2006.01); G01N 33/573 (2006.01)
CPC G01N 33/6896 (2013.01) [C12Q 1/32 (2013.01); C12Q 1/34 (2013.01); G01N 1/28 (2013.01); G01N 33/5076 (2013.01); G01N 33/573 (2013.01)] 10 Claims
 
1. An in vitro method for preparing a clinical human blood sample, the method comprising
(a) obtaining a preparation of isolated erythrocyte-derived extracellular vesicles (EEV) from a blood sample of a subject having or suspected of having Parkinson's disease;
(b) removing hemoglobin from the preparation of isolated EEV, thereby obtaining a processed blood sample depleted of hemoglobin; and
(c) quantifying the expression levels of one or more proteins in the processed blood sample of (b).